Microbiome Sequencing Services Market Size, Growth 2023-2032
The global microbiome sequencing services market was surpassed at USD 1.39 billion in 2022 and is expected to hit around USD 3.92 billion by 2032, growing at a CAGR of 10.93% from 2023 to 2032. By technology segment, the microbiome sequencing services market in the United States was estimated at USD 601.3 million in 2022.
Key Pointers
Report Scope of the Microbiome Sequencing Services Market
| Report Coverage | Details |
| Revenue Share of North America in 2022 | 47.86% |
| CAGR of Asia Pacific | 12.62% |
| Revenue Forecast by 2032 | USD 3.92 billion |
| Growth rate from 2023 to 2032 | CAGR of 10.93% |
| Base Year | 2022 |
| Forecast Period | 2023 to 2032 |
| Market Analysis (Terms Used) | Value (US$ Million/Billion) or (Volume/Units) |
| Companies Covered | Microbiome Insights Inc.; Baseclear BV; Clinical-Microbiomics A/S; Mérieux NutriSciences Corporation; MR DNA; Metabiomics Corp.; Rancho BioSciences; Second Genome; Zymo Research Corporation; uBiome, Inc. |
For instance, in October 2022, Danish microbiome research company, Clinical Microbiomics announced that venture capital firm Seventure Partners had invested €10 million ($9.7 million) in the company. The funds will be used by Clinical Microbiomics to advance the systems biology and microbiome profiling platforms, as well as to broaden the scope of their service offerings for multi-omics data integration and extend their reach internationally, starting with the US. Due to a large number of genomic initiatives for research and development, the market for microbiome sequencing services is growing.
With growing evidence that microbiomes have a significant effect on human health, the research on microbiome sequencing has advanced considerably in recent years. Studies investigating the variety of microbes that exist on and inside human bodies are now possible easily since there have been major improvements in sequencing technologies and significant declines in the costs of services. Furthermore, growing research on how the human body's microbiome influences certain aspects of human physiology provides enormous potential for the development of novel treatments and preventative measures for a wide range of diseases including cancer, mental health disorders, autoimmune conditions, and infectious diseases. This growing research on the microbiome is expected to drive the demand for microbiome sequencing services.
The COVID-19 pandemic has had positive effects on the market for microbiome sequencing services. Microbiome sequencing is mainly employed in the fields of infectious disease and cancer. The existence of the virus and the host's reaction to COVID-19 may be determined through RNA sequencing. Therefore, one of the key factors supporting its development in 2020 and beyond was the increasing adoption of microbiome sequencing tools during the COVID-19 pandemic.
Moreover,the government's partnerships with industry participants for extensive virus research also fueled the pandemic's high demand for microbiome sequencing. For instance, the UK established a genome sequencing partnership in March 2020 to facilitate rapid, comprehensive, and exhaustive sequencing analysis of samples from patients who tested positive for COVID-19. The network seeks to sequence every positive patient sample for the virus.
Technology Insights
Based on the technology, the sequencing by synthesis segment accounted for a significant share of 57.54% in 2022 and it is also anticipated to be the fastest-growing segment during the forecast period. Sequencing by synthesis (SBS), which has a highly parallel structure that enables the simultaneous sequencing of millions of amplicons, and resulted in a lot of interest in studying bacterial populations in the gut, skin, and other organs, each of which has a distinct microbial fingerprint. Since the sequencing by synthesis (SBS) is an extensively used method and is utilized by several commercial companies, it is expected to boost segmental revenue.
Application Insights
The gastrointestinal disorders segment is dominating the market with a revenue share of 54.05% in 2022. Studying the microbiome can help us better understand a number of gut-related diseases, such as Crohn's disease, diabetes, ulcerative colitis, and gastrointestinal cancers. Thus, the rising incidence of gut-related diseases globally is supplementing the segment revenue. Additionally, the advancement of cutting-edge sequencing technologies to study gut microbiota has also led to an increase in research and development, which contributes to segment growth.
The autoimmune disorder segment is the fastest-growing segment and is expected to witness notable growth at a CAGR of 13.02% by 2032. Since microbial composition alterations can result in the loss of immune tolerance, the human microbiome may play a significant role in autoimmunity. An estimated 3-5% of people globally have autoimmune diseases, which are caused when the immune system attacks one's own tissues. Furthermore, the growing demand for advanced microbiome sequencing services for the early detection of autoimmune diseases and growing awareness among healthcare professionals about these services' availability is expected to expedite segment growth over the forecast period.
End-user Insights
The academic research institutes segment accounted for the largest market share of 43.33% in 2022. The widespread application of microbiome sequencing services for protein, as well as small molecule analysis in research institutions and academics, contributes to the segment's high market share.
The pharmaceutical and biotechnology companies segment is the fastest growing segment and is expected to witness a CAGR of 12.47% by 2032. The demand for this segment is being fueled by factors including the substantial increase in R&D investments as well as the rise in the number of pharmaceutical and biopharmaceutical patents being granted globally.
Regional Insights
North America dominated the market in 2022 with revenue share of 47.86%. The market is expanding as a result of a growing number of cancer incidences in North America. One of the top ten primary causes of death in the US is cancer. For instance, According to the GLOBOCAN 2020 report, there will be roughly 2,281,658 instances of cancer overall in the U.S. in 2020. By 2040, there will likely be 366,572,150 instances, according to estimates. The North America market for microbiome sequencing services is also anticipated to expand due to the increasing need for these services owing to the ease of diagnosis and treatment.
The Asia Pacific region is anticipated to expand at the fastest CAGR of 12.62% over the forecast period due to the presence of major players. Additionally, the industry is growing as more individuals use different sequencing services for diagnosing diseases. Furthermore, growing funding in the countries such as Japan to study the microbiome and the relationship between microbes and disease states is expected to boost the demand for microbiome sequencing services in the Asia Pacific region.
Microbiome Sequencing Services Market Segmentations:
By Technology
By Application
By End-user
By Regional
Chapter 1. Introduction
1.1. Research Objective
1.2. Scope of the Study
1.3. Definition
Chapter 2. Research Methodology
2.1. Research Approach
2.2. Data Sources
2.3. Assumptions & Limitations
Chapter 3. Executive Summary
3.1. Market Snapshot
Chapter 4. Market Variables and Scope
4.1. Introduction
4.2. Market Classification and Scope
4.3. Industry Value Chain Analysis
4.3.1. Raw Material Procurement Analysis
4.3.2. Sales and Distribution Technology Analysis
4.3.3. Downstream Buyer Analysis
Chapter 5. COVID 19 Impact on Microbiome Sequencing Services Market
5.1. COVID-19 Landscape: Microbiome Sequencing Services Industry Impact
5.2. COVID 19 - Impact Assessment for the Industry
5.3. COVID 19 Impact: Global Major Government Policy
5.4. Market Trends and Opportunities in the COVID-19 Landscape
Chapter 6. Market Dynamics Analysis and Trends
6.1. Market Dynamics
6.1.1. Market Drivers
6.1.2. Market Restraints
6.1.3. Market Opportunities
6.2. Porter’s Five Forces Analysis
6.2.1. Bargaining power of suppliers
6.2.2. Bargaining power of buyers
6.2.3. Threat of substitute
6.2.4. Threat of new entrants
6.2.5. Degree of competition
Chapter 7. Competitive Landscape
7.1.1. Company Market Share/Positioning Analysis
7.1.2. Key Strategies Adopted by Players
7.1.3. Vendor Landscape
7.1.3.1. List of Suppliers
7.1.3.2. List of Buyers
Chapter 8. Global Microbiome Sequencing Services Market, By Technology
8.1. Microbiome Sequencing Services Market, by Technology, 2023-2032
8.1.1 Sequencing By Synthesis
8.1.1.1. Market Revenue and Forecast (2020-2032)
8.1.2. Sequencing By Ligation
8.1.2.1. Market Revenue and Forecast (2020-2032)
8.1.3. Sanger Sequencing
8.1.3.1. Market Revenue and Forecast (2020-2032)
8.1.4. Others
8.1.4.1. Market Revenue and Forecast (2020-2032)
Chapter 9. Global Microbiome Sequencing Services Market, By Application
9.1. Microbiome Sequencing Services Market, by Application, 2023-2032
9.1.1. Autoimmune Disorder
9.1.1.1. Market Revenue and Forecast (2020-2032)
9.1.2. Cancer
9.1.2.1. Market Revenue and Forecast (2020-2032)
9.1.3. Gastrointestinal Disorders
9.1.3.1. Market Revenue and Forecast (2020-2032)
9.1.4. Others
9.1.4.1. Market Revenue and Forecast (2020-2032)
Chapter 10. Global Microbiome Sequencing Services Market, By End-user
10.1. Microbiome Sequencing Services Market, by End-user, 2023-2032
10.1.1. Pharmaceutical & Biotechnology Companies
10.1.1.1. Market Revenue and Forecast (2020-2032)
10.1.2. Academic Research Institutes
10.1.2.1. Market Revenue and Forecast (2020-2032)
10.1.3. Others
10.1.3.1. Market Revenue and Forecast (2020-2032)
Chapter 11. Global Microbiome Sequencing Services Market, Regional Estimates and Trend Forecast
11.1. North America
11.1.1. Market Revenue and Forecast, by Technology (2020-2032)
11.1.2. Market Revenue and Forecast, by Application (2020-2032)
11.1.3. Market Revenue and Forecast, by End-user (2020-2032)
11.1.4. U.S.
11.1.4.1. Market Revenue and Forecast, by Technology (2020-2032)
11.1.4.2. Market Revenue and Forecast, by Application (2020-2032)
11.1.4.3. Market Revenue and Forecast, by End-user (2020-2032)
11.1.5. Rest of North America
11.1.5.1. Market Revenue and Forecast, by Technology (2020-2032)
11.1.5.2. Market Revenue and Forecast, by Application (2020-2032)
11.1.5.3. Market Revenue and Forecast, by End-user (2020-2032)
11.2. Europe
11.2.1. Market Revenue and Forecast, by Technology (2020-2032)
11.2.2. Market Revenue and Forecast, by Application (2020-2032)
11.2.3. Market Revenue and Forecast, by End-user (2020-2032)
11.2.4. UK
11.2.4.1. Market Revenue and Forecast, by Technology (2020-2032)
11.2.4.2. Market Revenue and Forecast, by Application (2020-2032)
11.2.4.3. Market Revenue and Forecast, by End-user (2020-2032)
11.2.5. Germany
11.2.5.1. Market Revenue and Forecast, by Technology (2020-2032)
11.2.5.2. Market Revenue and Forecast, by Application (2020-2032)
11.2.5.3. Market Revenue and Forecast, by End-user (2020-2032)
11.2.6. France
11.2.6.1. Market Revenue and Forecast, by Technology (2020-2032)
11.2.6.2. Market Revenue and Forecast, by Application (2020-2032)
11.2.6.3. Market Revenue and Forecast, by End-user (2020-2032)
11.2.7. Rest of Europe
11.2.7.1. Market Revenue and Forecast, by Technology (2020-2032)
11.2.7.2. Market Revenue and Forecast, by Application (2020-2032)
11.2.7.3. Market Revenue and Forecast, by End-user (2020-2032)
11.3. APAC
11.3.1. Market Revenue and Forecast, by Technology (2020-2032)
11.3.2. Market Revenue and Forecast, by Application (2020-2032)
11.3.3. Market Revenue and Forecast, by End-user (2020-2032)
11.3.4. India
11.3.4.1. Market Revenue and Forecast, by Technology (2020-2032)
11.3.4.2. Market Revenue and Forecast, by Application (2020-2032)
11.3.4.3. Market Revenue and Forecast, by End-user (2020-2032)
11.3.5. China
11.3.5.1. Market Revenue and Forecast, by Technology (2020-2032)
11.3.5.2. Market Revenue and Forecast, by Application (2020-2032)
11.3.5.3. Market Revenue and Forecast, by End-user (2020-2032)
11.3.6. Japan
11.3.6.1. Market Revenue and Forecast, by Technology (2020-2032)
11.3.6.2. Market Revenue and Forecast, by Application (2020-2032)
11.3.6.3. Market Revenue and Forecast, by End-user (2020-2032)
11.3.7. Rest of APAC
11.3.7.1. Market Revenue and Forecast, by Technology (2020-2032)
11.3.7.2. Market Revenue and Forecast, by Application (2020-2032)
11.3.7.3. Market Revenue and Forecast, by End-user (2020-2032)
11.4. MEA
11.4.1. Market Revenue and Forecast, by Technology (2020-2032)
11.4.2. Market Revenue and Forecast, by Application (2020-2032)
11.4.3. Market Revenue and Forecast, by End-user (2020-2032)
11.4.4. GCC
11.4.4.1. Market Revenue and Forecast, by Technology (2020-2032)
11.4.4.2. Market Revenue and Forecast, by Application (2020-2032)
11.4.4.3. Market Revenue and Forecast, by End-user (2020-2032)
11.4.5. North Africa
11.4.5.1. Market Revenue and Forecast, by Technology (2020-2032)
11.4.5.2. Market Revenue and Forecast, by Application (2020-2032)
11.4.5.3. Market Revenue and Forecast, by End-user (2020-2032)
11.4.6. South Africa
11.4.6.1. Market Revenue and Forecast, by Technology (2020-2032)
11.4.6.2. Market Revenue and Forecast, by Application (2020-2032)
11.4.6.3. Market Revenue and Forecast, by End-user (2020-2032)
11.4.7. Rest of MEA
11.4.7.1. Market Revenue and Forecast, by Technology (2020-2032)
11.4.7.2. Market Revenue and Forecast, by Application (2020-2032)
11.4.7.3. Market Revenue and Forecast, by End-user (2020-2032)
11.5. Latin America
11.5.1. Market Revenue and Forecast, by Technology (2020-2032)
11.5.2. Market Revenue and Forecast, by Application (2020-2032)
11.5.3. Market Revenue and Forecast, by End-user (2020-2032)
11.5.4. Brazil
11.5.4.1. Market Revenue and Forecast, by Technology (2020-2032)
11.5.4.2. Market Revenue and Forecast, by Application (2020-2032)
11.5.4.3. Market Revenue and Forecast, by End-user (2020-2032)
11.5.5. Rest of LATAM
11.5.5.1. Market Revenue and Forecast, by Technology (2020-2032)
11.5.5.2. Market Revenue and Forecast, by Application (2020-2032)
11.5.5.3. Market Revenue and Forecast, by End-user (2020-2032)
Chapter 12. Company Profiles
12.1. Microbiome Insights Inc.
12.1.1. Company Overview
12.1.2. Product Offerings
12.1.3. Financial Performance
12.1.4. Recent Initiatives
12.2. Baseclear BV
12.2.1. Company Overview
12.2.2. Product Offerings
12.2.3. Financial Performance
12.2.4. Recent Initiatives
12.3. Clinical-Microbiomics A/S
12.3.1. Company Overview
12.3.2. Product Offerings
12.3.3. Financial Performance
12.3.4. Recent Initiatives
12.4. Mérieux NutriSciences Corporation
12.4.1. Company Overview
12.4.2. Product Offerings
12.4.3. Financial Performance
12.4.4. Recent Initiatives
12.5. MR DNA
12.5.1. Company Overview
12.5.2. Product Offerings
12.5.3. Financial Performance
12.5.4. Recent Initiatives
12.6. Metabiomics Corp.
12.6.1. Company Overview
12.6.2. Product Offerings
12.6.3. Financial Performance
12.6.4. Recent Initiatives
12.7. Rancho BioSciences
12.7.1. Company Overview
12.7.2. Product Offerings
12.7.3. Financial Performance
12.7.4. Recent Initiatives
12.8. Second Genome
12.8.1. Company Overview
12.8.2. Product Offerings
12.8.3. Financial Performance
12.8.4. Recent Initiatives
12.9. Zymo Research Corporation
12.9.1. Company Overview
12.9.2. Product Offerings
12.9.3. Financial Performance
12.9.4. Recent Initiatives
12.10. uBiome, Inc.
12.10.1. Company Overview
12.10.2. Product Offerings
12.10.3. Financial Performance
12.10.4. Recent Initiatives
Chapter 13. Research Methodology
13.1. Primary Research
13.2. Secondary Research
13.3. Assumptions
Chapter 14. Appendix
14.1. About Us
14.2. Glossary of Terms
Cross-segment Market Size and Analysis for
Mentioned Segments
Additional Company Profiles (Upto 5 With No Cost)
Additional Countries (Apart From Mentioned Countries)
Country/Region-specific Report
Go To Market Strategy
Region Specific Market DynamicsRegion Level Market Share Import Export AnalysisProduction AnalysisOthers